BLOG

Key Criteria for Choosing a Safe Stem Cell Clinic in Japan

8 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

With its advanced medical technology and stringent regulatory standards, Japan has become a prominent destination for patients seeking regenerative medicine, including stem cell therapy. For international patients, navigating the landscape of available clinics can be challenging. Making an informed decision is crucial, not only for the potential effectiveness of the treatment but, more importantly, for ensuring safety. This article provides a guide on the key criteria to consider when choosing a clinic for stem cell therapy in Japan, with a focus on the legal framework that governs this innovative field.

Understanding Japan’s Key Regulation: The Act on the Safety of Regenerative Medicine

The cornerstone of patient safety for regenerative medicine in Japan is the “Act on the Safety of Regenerative Medicine” (ASRM), which was enacted in 2014. This law establishes a comprehensive framework to ensure that stem cell therapies and other regenerative treatments are provided responsibly. Its primary goal is to balance the promotion of new medical technologies with the protection of patient health. Under this Act, all medical institutions providing regenerative medicine must submit a detailed treatment plan to Japan’s Ministry of Health, Labour and Welfare (MHLW).

This plan is categorized based on risk level (low, medium, or high) and must be reviewed by a certified, independent ethics committee before it can be submitted to the MHLW. Only after the plan is officially accepted by the government can the clinic begin offering the treatment. This legal requirement is the single most important factor distinguishing a compliant, safety-conscious clinic from one that may be operating outside of established standards.

Essential Checklist: How to Verify a Clinic’s Compliance and Safety

When researching clinics, international patients should look for clear evidence of compliance with Japanese law. Here are the essential points to verify:

  • MHLW Notification Number: A compliant clinic must have its regenerative medicine provision plan accepted by the MHLW. The clinic should be able to provide the official notification number for the specific therapy you are considering. The existence of this number confirms that the treatment protocol has passed the required legal and ethical reviews.
  • Use of a Certified Cell Processing Center (CPC): The process of isolating, culturing, and expanding stem cells must be conducted in a specialized facility known as a Cell Processing Center (CPC). These facilities must also be licensed and adhere to strict standards for safety, quality control, and hygiene to prevent contamination and ensure cell viability. Ask the clinic whether they use an in-house or outsourced CPC and confirm that the facility is properly certified.
  • Independent Ethics Committee Review: Every treatment plan must be evaluated by a Certified Regenerative Medicine Committee. This committee is required to be independent of the medical institution providing the care. Its role is to assess the scientific rationale, ethical considerations, and safety protocols of the proposed treatment. This third-party oversight is a critical safeguard for patients.
  • Thorough Informed Consent: A reputable clinic will prioritize a comprehensive informed consent process. The physician should explain in detail the procedure, the expected outcomes, potential benefits, and all known risks and side effects. You should never feel pressured to make a decision. The process must be documented, and you will be required to sign a consent form before any treatment begins.

Focus on Adipose-Derived Stem Cell Therapy

One common type of stem cell therapy offered in Japan is Adipose-Derived Stem Cell (ADSC) Therapy. This treatment involves collecting a small amount of fat tissue from the patient, isolating the mesenchymal stem cells (MSCs) it contains, expanding their numbers in a CPC, and then administering them back to the patient, typically through an intravenous (IV) infusion. Because the cells are autologous (your own), the risk of rejection or allergic reactions is considered to be low.

It is important to understand that ADSC therapy is provided as a treatment not covered by public health insurance (known as “jiyu-shinryo” or private practice). This means patients are responsible for the full cost of the treatment. The applicability, potential effects, risks, and side effects of this therapy must be carefully discussed with and evaluated by a physician based on your individual health condition.

Questions to Ask Before Making a Decision

A consultation with a physician is a critical step. To make an informed choice, be prepared to ask specific questions. Here are some key points to cover:

  • Based on my medical history and current condition, am I a suitable candidate for this therapy?
  • What are the potential benefits and risks in my specific case?
  • Could you explain the entire process, from cell collection and processing to the final administration?
  • What is the total cost of the treatment plan, and what does it include (e.g., consultations, tests, cell processing, administration, follow-up)?
  • What kind of follow-up care and monitoring is provided after the treatment?
  • Can you provide the MHLW notification number for this treatment plan?

The physician’s willingness to answer these questions transparently is a good indicator of the clinic’s professionalism and commitment to patient care. Any claims of guaranteed cures or promises of effectiveness that seem too good to be true should be viewed with caution. This therapy is not a replacement for standard medical treatments for specific diseases, and its effects can vary between individuals.

Our Approach at Grand Green Osaka Umekita Clinic

At Grand Green Osaka Umekita Clinic, located in the heart of Osaka, we provide Adipose-Derived Stem Cell Therapy in strict compliance with the Act on the Safety of Regenerative Medicine. Our treatment plans are officially accepted by the Ministry of Health, Labour and Welfare, and we partner with a certified Cell Processing Center to ensure the quality and safety of the cells we administer. We are committed to providing clear, detailed information to help our patients, including those from overseas, make decisions that are right for them.

Our team believes that a well-informed patient is an empowered patient. We encourage a thorough discussion with our physicians to review your health status, treatment goals, and any concerns you may have. For more details on our Adipose-Derived Stem Cell Therapy, including the treatment process and other considerations, please visit our dedicated page.

Learn more about Adipose-Derived Stem Cell Therapy at our clinic.

Conclusion: Making an Informed Choice for Your Health

Choosing a clinic for stem cell therapy in Japan requires careful research and due diligence. By focusing on clinics that operate transparently within the legal framework of the Act on the Safety of Regenerative Medicine, you can significantly mitigate risks. Always verify a clinic’s MHLW notification, their use of a certified CPC, and the presence of third-party ethical oversight. A final decision should only be made after a comprehensive consultation with a qualified physician who can assess your individual needs and provide realistic expectations. Your health is your most valuable asset, and an informed choice is the best way to protect it.

Learn more about Adipose-Derived Stem Cell Therapy

References

Supervising Physician

Hidenori Shimada

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to Adipose-Derived Stem Cell Therapy ›

Grand Green Osaka South Building, Gate Tower 5F 5-54 Ofuka-cho, Kita-ku, Osaka 530-0011, Japan

TEL: 06-7653-8493 FAX: 06-7635-8052

Contact